Document Detail


Oral phentolamine: an alpha-1, alpha-2 adrenergic antagonist for the treatment of erectile dysfunction.
MedLine Citation:
PMID:  10849569     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Phentolamine mesylate is an alpha-1 and alpha-2 selective adrenergic receptor antagonist which has undergone clinical trials for erectile dysfunction treatment. Biochemical and physiological studies in human erectile tissue have revealed a high affinity of phentolamine for alpha-1 and alpha-2 adrenergic receptors. Based on pharmacokinetic studies, it is suggested that 30-40 min following oral ingestion of 40 or 80 mg of phentolamine (Vasomax), the mean plasma phentolamine concentrations are sufficient to occupy the alpha-1 and -2 adrenergic receptors in erectile tissue and thereby result in inhibition of adrenergic-mediated physiologic activity. In large multi-center, placebo-controlled pivotal phase III clinical trials, the mean change in the erectile function domain of the International Index of Erectile Function scores (Questions 1-5 and 15) from screening to the end of treatment was significantly higher following use of active drug (40 mg and 80 mg) compared to placebo. Three to four times as many patients receiving phentolamine reported being satisfied or very satisfied compared with those receiving placebo. At doses of 40 mg and 80 mg respectively, 55% and 59% of men were able to achieve vaginal penetration with 51% and 53% achieving penetration on 75% of attempts. The correction of erectile dysfunction or improvement to a less severe category of dysfunction was experienced by 53% of men with the 80 mg dose and 40% with the 40 mg dose of phentolamine. All trends of response were the same regardless of any concomitant medication. There were no severe adverse events. At 40 mg, 7.7% experienced rhinitis and fewer than 3.1% experienced any other side effect of treatment. Phentolamine is safe, well tolerated and efficacious for the treatment of erectile dysfunction. International Journal of Impotence Research (2000) 12, Suppl 1, S75-S80
Authors:
Goldstein
Related Documents :
24613569 - Placement of empty catheters for an hdr-emulating ldr prostate brachytherapy technique:...
17388709 - Rapid versus conventional initiation of quetiapine in the treatment of schizophrenia: a...
7838889 - Bms-181168 for protection of the human brain against hypoxia: double-blind, placebo-con...
6235249 - Gastrointestinal microbleeding associated with the use of etodolac, ibuprofen, indometh...
9825369 - Conversion of recent-onset atrial fibrillation to sinus rhythm: effects of different dr...
16212139 - Upper gastrointestinal tract safety of daily oral risedronate in patients taking nsaids...
8655889 - Airway responsiveness after a single dose of salmeterol and during four months of treat...
18167109 - Evaluation of neoadjuvant prednisone administration and surgical excision in treatment ...
20371199 - Effects of multiple oral dosing of itraconazole on the pharmacokinetics of cyclosporine...
Publication Detail:
Type:  JOURNAL ARTICLE    
Journal Detail:
Title:  International journal of impotence research     Volume:  12     ISSN:  1476-5489     ISO Abbreviation:  Int. J. Impot. Res.     Publication Date:  2000 Mar 
Date Detail:
Created Date:  2000-06-12     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9007383     Medline TA:  Int J Impot Res     Country:  -    
Other Details:
Languages:  ENG     Pagination:  S75-S80     Citation Subset:  -    
Affiliation:
Department of Urology, Boston University School of Medicine, Boston, MA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Yohimbine in erectile dysfunction: the facts.
Next Document:  Comparison of oral and intracavernosal vasoactive agents in penile erection.